What You Should Know:
- Absci Corporation (Nasdaq: ABSI), a company utilizing generative AI for drug discovery, announced today an initial public offering (IPO) of $75 million in common stock.
- This IPO aims to support the advancement of Absci's internal drug development programs, further investment in their Integrated Drug Creation™ platform, and general corporate purposes.
Offering Details
Absci intends to offer $75M of common stock, with an option to sell an additional $11.25M
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Veradigm Acquires ScienceIO for $140M in Cash to Accelerate AI Innovation in Healthcare
What You Should Know:
- Veradigm Inc. (NASDAQ: MDRX), a provider of healthcare data and technology solutions, announced an agreement to acquire ScienceIO, a leader in healthcare AI platform and foundation models.
- The acquisition is valued at $140 million in cash, with $44 million deferred and payable in installments over three years. Veradigm will fund the transaction entirely from existing cash reserves.
Strategic Acquisition to Enhance AI Capabilities
This acquisition signifies
Read More
How to Use NBA in Pharma Sales: Best Practices
Next Best Action has been one of the most important approaches for sales in recent years, including for pharmaceuticals. But because selling pharma is significantly different than selling other products, pharma-oriented NBA approaches need to be significantly more sophisticated than NBA for other industries. Pharma sales teams looking to implement NBA need to embrace an updated, data-driven version of this approach, known as NBA 2.0,
Read More
Alamar Biosciences Raises $128M to Accelerate Proteomics Platform
What You Should Know:
- Alamar Biosciences, a leader in precision proteomics for early disease detection raises $100M in Series C round, with an additional $28M expected within the next 30 days. This brings their total funding to nearly $250M.
- The Series C funding round was led by led by Sands Capital, with participation from new and existing investors, including both financial and strategic partners. Ian Ratcliffe, Executive Managing Partner at Sands Capital, has joined Alamar's Board
Read More
Power Secures $11.9M to Democratize Clinical Trials
What You Should Know:
- Power, the company transforming the traditional clinical trial landscape, announced today the close of their $11.9M Series A funding round led by Kin, Contrary, and Footwork.
- The strategic funding fuels Power's mission to democratize access to clinical trials and diversify the pool of participants, ultimately accelerating life-saving medical research.
Revolutionizing Clinical Trial Participation
Founded in 2021 by Brandon Li and Michael Gill, Power
Read More
FDA Clears Proscia’s Digital Pathology Solution for Cancer Diagnosis
What You Should Know:
Proscia, a leading provider of digital and computational pathology solutions, has received 510(k) clearance from the United States (U.S.) Food and Drug Administration (FDA) for its Concentriq® AP-Dx*. The digital pathology solution was cleared for the purpose of primary diagnosis.Proscia’s Concentriq AP-Dx is a comprehensive diagnostic software solution that immerses pathologists in an intuitive experience for viewing, interpreting, and managing whole slide images
Read More
Freenome Raises $254M to Accelerate Early Cancer Detection Platform
What You Should Know:
- Freenome, a leader in blood-based early cancer detection, has raised $254M in a new funding round, fueled by its innovative multiomics platform and promising pipeline of tests. The funding was led by Roche with participation from a16z Life Sciences Growth Fund, the American Cancer Society’s BrightEdge Ventures, ARK Investments, ArrowMark Partners, Artis Ventures, Bain Capital Life Sciences, Cormorant Capital, DCVC, Eventide Asset Management LLC, Intermountain Ventures,
Read More
Headlight Mental Health Scores $18M to Expand Teletherapy, In-Person Care
What You Should Know:
Headlight, a tech-forward mental health practice committed to offering patients convenience and a simplified care journey, today announced $18 million in new venture funding, led by Matrix and EPIC Ventures.Funding will help the company expand into additional states and add hundreds of new licensed therapists to their team by 2025. Prior to the transaction, Headlight added new executive leadership including Chief Executive Officer Geoff Swindle, former Chief
Read More
How Open-Source Technologies Will Transform Digital Clinical Trials
Although the traditional nearly decade-long clinical trial timelines completely collapsed during COVID, this truncating was not necessarily novel. Precedent exists for accelerating approval timelines during health emergencies such as the AIDs/HIV epidemic, where Compound S, a re-make of AZT, or azidothymidine, originally developed to fight cancer, became controversially fast-tracked after the discovery that it could block HIV activity. Likewise, when potentially lifesaving drugs are
Read More
Unlearn Raises $50M to Accelerate AI-Powered Clinical Trials with Digital Twins
What You Should Know:
- Unlearn®, a leading AI company using digital twins to revolutionize clinical trials, announced today a $50M Series C funding round led by Altimeter Capital. This investment, bringing Unlearn's total funding to over $130M, will fuel its mission to eliminate trial and error in medicine through faster, smaller, and more ethical clinical trials.
- Unlearn collaborates with pharmaceutical companies, biotechs, and academic institutions to optimize and streamline clinical
Read More
